Tag: tonix pharmaceuticals stock
How the Mallinckrods Found the Future of Medicine
In the summer of 1892, a little girl named Mary was diagnosed with rheumatoid arthritis.The news sent a shock wave through the town of Madrigal, Minnesota.At first, the girl was left in a wheelchair and bedridden for several months.The doctors at the local hospital had no idea what to do with her.But the more they […]
Continue Reading...
How to buy stock at an ‘overvalued’ company
The stock market’s valuation is based on the expectation of a company’s future earnings, but it also factors in the impact of a drug’s price on its market value.The latest edition of Forbes’ stock market report, released on Monday, shows that the stock market is undervalued by a whopping $6.4 billion in 2018.Here’s how you […]
Continue Reading...
How to make a profit in a fast-growing niche
The fast-moving, lucrative niche of healthcare is poised to become one of the fastest-growing sectors of the global economy.Analysts expect that the sector could generate $2 trillion of annual growth by 2021, while the US could generate another $600 billion in revenue in 2021.But analysts say the industry faces a number of challenges.It is not […]
Continue Reading...
Gilead Pharmaceuticals stock gains on strong outlook for next year
Gilean Pharmaceuticals is getting another dose of life back, after a disappointing year.The drugmaker reported fourth-quarter profit of $2.05 per share, beating analysts’ estimates of $1.88 per share.Gileas stock jumped nearly 6% to $37.50 per share after the earnings.Analysts had forecast earnings of $3.05 to $3,11 per share for the quarter.“We have a lot of […]
Continue Reading...
Which pharmaceutical companies are the most profitable in the world?
The most profitable companies in the global pharmaceutical industry are based in China, according to a new report released Tuesday.The research firm IHS Markit, which is based in New York, has compiled a list of the world’s 100 most profitable pharmaceutical companies based on gross profits.Among the top 10 were AstraZeneca ($1.8 billion), Bristol-Myers Squibb […]
Continue Reading...